Table 1.

Advances in CAR-T cell therapy for hematologic malignancies from ESMO2024

Agent	Drug type	Study type	Disease	Accrual	Median follow-up duration	Efficacy	Major AEs	References
ssCART-19	Autologous IL-6-knockdown CD19 CAR-T	Phase I trial (NCT04825496)	R/R B-cell ALL	17 (58.8% having over 50% blasts)	19.6 m	ORR 87.5% (CR 62.5%, CRi 25.0%) within 3 m; 6-m DOR at 100% for DL1, 80% for DL2, 0% for DL3; median OS not reached	No grade ≥ 4 CRS, ICANS or related deaths	[3]
NT-I7	Long-acting IL-7 following CD19 CAR-T	Phase Ib trial (NCT05075603)	Advanced DLBCL	11 (mean age 67, 81.8% III-IV stage)	N/A	ORR 81.1% (CR 63.6%); median OS 363 d; median PFS 92 d; dosed at day 21 after CAR-T infusion enhanced expansion, persistence and stemness	No CRS or ICANS	[4]
Tisagenlecleucel	Autologous CD19 CAR-T	Real-world study	R/R FL	129 (66.7% male, median age 63.7, median 3 prior treatment lines, 78.0% refractory, 75.0% relapsed in 6 m)	9.8 m	ORR 98.2% (best CR 85.8%); 1.8% progression as best response; 12-m PFS 62.6%, 12-m OS 84.9%, both medians not reached	< 1% grade 3–4 CRS and/or ICANS; no adverse drug reactions led to death	[5]
Idecabtagene vicleucel/ ciltacabtagene autoleucel vs. teclistamab	Autologous BCMA CAR-T vs. bispecifics	Real-world study	R/R MM	391 (277 idecabtagene vicleucel, 114 ciltacabtagene autoleucel) vs. 458 (mean age 66, 54% male)	N/A	Better OS in CAR-T; older (age ≥ 70) and transplant-ineligible patients benefited more from CAR-T	More CRS in CAR-T but similar ICANS	[6]

Abbreviations CAR, chimeric antigen receptor; AE, adverse event; R/R, relapsed/refractory; ALL, acute lymphoblastic leukemia; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; ORR, overall response rate; CR, complete response; CRi, complete response with incomplete hematologic recovery; DOR, duration of response; DL, dose level; OS, overall survival; DLBCL, diffuse large B-cell lymphoma; N/A, not applicable or not available; PFS, progression-free survival; FL, follicular lymphoma; BCMA, B-cell maturation antigen; MM, multiple myeloma